Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. - Cook G; Ashcroft AJ; Senior E; Olivier C; Hockaday A; Richards J; Cavenagh JD; Snowden JA; Drayson MT; de Tute R; Roberts L; Owen RG; et al. (The Lancet. Haematology, 2024)